hypothesis is attractive because it presents a framework tive splicing events that produce structural changes in to account for the fine control of splicing events obproteins important for the ability of these cells to comserved in natural systems. The study of developmentally municate electrical and chemical signals (ion channels, induced changes in splicing regulation in the rat cerereceptors, neurotransmitters), and to develop synapbellum illustrates the gradual changes, both increases tic connections (neurotransmitter receptors). In some and decreases in neural exon selection, for a variety of cases, the change in protein function is known to be substrates in a time frame that overlaps with synaptoexquisitely specific in affecting the kinetics of ion changenesis (Wang and Grabowski, 1996) . These splicing nel gating (Lin et al., 1997) or the location of protein changes are both coordinated and tissue-specific. How isoforms at the postsynaptic membrane (Ehlers et al., do splicing regulatory pathways respond to develop-1995) . In most cases, however, there are changes immental signals? A single cell PCR analysis over the same posed by splicing for which there are no known functime frame further illustrates that there are significant tional consequences. Understanding the biological imdifferences in the extent of splicing regulation in Purkinje pact of neuron-specific splicing offers many interesting and granule neurons and that this effect is gene-specific. challenges, but this is the tip of the iceberg. Additional Differences in splicing are also noted for distinct neuquestions of a mechanistic nature drive current research rons of aplysia (Buck et al., 1987) . How is splicing regulaand stimulate ideas in this area. What is the molecular tion adjusted in different neurons? The conclusion from basis of the neural specificity of splicing? How is splicing these studies is that the biology of regulated splicing regulation modulated or tuned in different neurons? How events in neurons is more interesting than models of do developmental programs coordinate splicing regulaon/off regulation would indicate, and this fits well with tory pathways? more complex scenarios that superimpose positive and The Complex Language of RNA Regulatory Signals negative control.
and the Importance of Negative Control
What is the evidence for the complex arrangement of From recent studies of cassette exons that are spliced opposing RNA signals and how can we make sense of in neuronal cells and not in other cell types, one thing this RNA language? A complex arrangement of positive and negative regulatory RNA signals is illustrated by the is clear. There is no simple answer to the origin of the N1 exon of c-src and the 24 nucleotide exon of the ␥2 neural specificity of splicing. For the framework of dissubunit of the GABA A receptor, both neuron-specific cussion, and with an emphasis on simple, two models cassette exons. Positive regulatory elements identified can be proposed to account for neuron-specific splicing by in vivo expression assays in neuronal cell lines are of a cassette exon. Neurons contain a specialized activlocated near and/or within the neural exon, but are otherity that promotes selection of the neuron-specific exon, wise distinct from one another and from known splicing whereas nonneuronal cells have little or none of this signals (Black, 1992; Zhang et al., 1996) . For c-src, the activity (positive regulation model). Alternatively, nonkey positive regulatory sequence is an intron enhancer neuronal cells contain an activity that represses (neuronpositioned in the downstream intron, whereas for ␥2, the specific) exon selection, and this activity is missing or regulatory region contains an element in the upstream less abundant in neurons (negative regulation model).
intron and one in the neural exon itself. Despite the When taken at face value, the negative regulation model lack of similarity of the positive signals, the negative makes the unsettling prediction that specialized factors elements provide a unifying theme. Two recent studies in neurons are not necessarily required to account for provide functional evidence for negative regulation the neural specificity. Rather a difference in the level or (Ashiya and Grabowski, 1997; Chan and Black, 1997) . activity of repressor machineries in neurons may be all
In c-src, two repressor signals are localized in the polythat is needed to account for the cell specificity. The pyrimidine tract just upstream of the neural exon, and current status of work in this area, although quantum two additional sites are found in the intron enhancer jumps away from providing a comprehensive underregion. In ␥2, three repressor signals surround the standing of regulatory mechanisms, paints a more interbranch site of the neural exon and a fourth overlaps with esting picture than any single model would indicate. a positive element in the neural exon. The paradigm that emerges from several recent studShifting the Balance to Positive Regulation ies is that the RNA regulatory regions that encompass in Neurons: hnRNP Proteins the neuron-specific exon and adjacent intron regions as Splicing Regulators contain a complex arrangement of opposing signals that
The repressor sequences from both c-src and ␥2 premRNAs are rich in pyrimidine residues and contain one allow for positive and negative control mechanisms to Schematic illustrates a pre-mRNA region containing a neuron-specific cassette exon (shaded box) and flanking intron/exon regions. RNA signals that repress splicing of the neural exon bind avidly to the hnRNP protein, PTB. The negative signals are arranged in clusters that overlap with cell-specific signals required for splicing of the neural exon (RNA regulatory region; thin boxes). The RNA regulatory region includes binding sites for general splicing components, such as U2 snRNP and U2AF, at the branch site/3Ј splice site region, as well as U1 snRNP at the 5Ј splice site. A central question is, how are interactions of general splicing components at the splice sites of the neural exon modulated by repressors in nonneuronal cells, including PTB, and by activating mechanisms in neurons? Activating factors responsible for shifting the balance of control to the neural splicing pathway are largely unidentified. KSRP, a KH-type RNA-binding protein, is enriched in neuronal cells and regulates splicing of the c-src neural exon through recognition of intron enhancer sequences in the downstream portion of the regulatory region. PTB-binding sites overlap with neuron-specific regulatory signals, including the c-src intron enhancer sequence, and with the U2AF-binding region. On/off models are not sufficient to account for the gradient of splicing regulation observed for some neural exons during development, or in distinct neuronal cell types (graph).
or more of the following motifs in a larger pyrimidine reported in studies of muscle-specific splicing events. So, it is not likely that PTB alone accounts for the neural context-CUCUCU, UUCUCU, UUCCUU, CUUCUUC. Repressor sequences in the form of short RNA competispecificity of splicing. Nonetheless, there is the interesting observation that nuclear extracts derived from rat tors function to switch splicing to the neural pathway when added to HeLa splicing extracts together with brain and neuronal cells in culture express different forms of PTB, compared to HeLa cells and rat kidney radiolabeled pre-mRNA. These RNA competitors show specific binding to the polypyrimidine tract-binding pro- (Ashiya and Grabowski, 1997; Chan and Black, 1997) . Three known isoforms of human PTB have been cloned, tein (PTB), and there is good agreement between the strength of PTB binding and the magnitude of the splic-PTB1, PTB2, and PTB4/hnRNP I, and these differ in the length of the linker region between the first and second ing switch. Additional evidence for the involvement of PTB is provided by gain-of-function experiments in two RNA recognition domains. It is not known if these isoforms differ in their ability to confer repression, or to which repression is reestablished by addition of excess PTB together with the RNA competitor. These results interact with protein partners. If there is truly a different distribution of PTB isoforms in neurons (the precise difdemonstrate a requirement for PTB, but do not address whether PTB is sufficient to establish repression. More ferences in protein structure and distribution need to be nailed down further), the question of functional differrigorous tests need to be applied to address this issue and to assess the relevance of these repressive mechaences in repression for the various isoforms will be especially relevant to address. nisms to living cells.
The mechanism by which the RNA competitors drive PTB is a member of the large family of hnRNP proteins, originally viewed in electron micrographs as beads on the dissociation of PTB from pre-mRNA repressor sites is likely to occur by simple mass action. Once the represa string in their association with nuclear pre-mRNA (see Dreyfuss et al., 1993, for review) . An earlier hypothesis sor sites are vacated, the overlapping positive signals are made available for interaction with general splicing that hnRNP particles are nonspecific structures to compact and protect RNA from nucleolytic degradation has factors in the HeLa extract. For ␥2 pre-mRNA, neuronspecific factors have not yet been identified, and it is long been held as too narrow a view. A variety of hnRNP proteins are known to bind at specific RNA sequences, too early to rule out a simple derepression model in neuronal cells.
including pre-mRNA splice sites, and some are splicing regulators. The involvement of PTB in splicing represHow do mechanisms of repression, and PTB effects in particular, account for the neural specificity of splicsion lends further strength to the idea that "hnRNP structure" is both specific and dynamic, and calls to mind ing? It is important to point out that the evidence for the involvement of PTB in splicing repression was first an obvious analogy to chromatin. Some neuronal cells might contain lower levels of PTB, or an altered distribucorrelation between specific splicing defects and human disease. These previous reports show that mutations in tion of isoforms. Alternatively, there might be activities in neuronal cells that disrupt splicing repressor complexes splice sites, or in internal intron regions, exist in the chromosomal copy of the gene, and it is virtually certain after their assembly with pre-mRNA, analogous to the disruption of nucleosomes at promoter sites during tranthat these mutations account for the aberrant splicing events. What is striking about the Lin et al. (1998) study scriptional activation.
An important advance in the field is represented by is that there are multiple splicing defects that do not correlate with any mutations in the EAAT2 gene. The the discovery of the neural splicing regulator, KSRP, which binds to the intron enhancer region of the c-src sequences of the splice site regions were checked with particular care and found to be intact. Moreover, these pre-mRNA and mediates splicing of the neural exon (Min et al., 1997) . The identification of KSRP stems from a defects show a striking regional specificity in the brain. Splicing defects in EAAT2 mRNA are observed in postcareful analysis of protein components that assemble in neuronal nuclear extracts with a short RNA containmortem samples of the motor cortex, but not in the cerebellum or hippocampus of the same individuals. ing the core intron enhancer sequence. KSRP is enriched, but not exclusively expressed, in neuronal cells, These defects are not found in normal brain or in individuals with neurodegenerative diseases other than ALS. and additional components of the complex, including hnRNP F, are ubiquitously expressed. The sequence of Interest in the cellular (astrocyte) specificity of the defects is tempered by the fact that the expression of KSRP shows that it contains unusual RNA-binding motifs of the KH type and bears similarity to hnRNP K. This EAAT2 (mRNA and protein) is known to be restricted to astrocytes in the brain. similarity to hnRNP K and a distribution among different cell types suggest that KSRP is an hnRNP-type of splicHow strong is the evidence for splicing defects in EAAT2 mRNA? This study employs the reverse-traning regulator. Although not exclusively neuronal, higher levels of KSRP in neurons might shift the balance of scriptase polymerase chain reaction to amplify EAAT2 mRNA sequences using as template poly(A) ϩ mRNA control by engaging positive RNA signals at the expense of repressor binding. The fact that the c-src intron enfrom the motor cortex of individuals with ALS. Multiple specific exon deletions are found from sequencing the hancer contains two repressor sequences suggests that KSRP must somehow displace or compete for PTB bindcloned DNA products, whereas the full-length cDNA is amplified from other brain regions of the same individual ing to the regulatory region. Current evidence indicates that KSRP functions in conjunction with a specific subor from normal control samples. Similar EAAT2 mRNA defects are observed from 19 additional patients with set of intron enhancers, which suggests that the regulatory functions of this protein are highly specific. Several ALS, and these too are restricted to the motor cortex. Nuclease S1 analysis provides additional evidence for comprehensive reviews describe the properties of distinct splicing enhancer elements and their interacting specific splicing defects that result in exon skipping. When these results are quantified an impressive fraction proteins (Fu, 1995; Manley and Tacke, 1996) . In addition, one recent study describes a complex intron enhancer (70%) of the EAAT2 mRNA is found to be defective. Two specific mRNA defects stand out in this study. involved in the activation of neuron-specific processing of calcitonin/CGRP pre-mRNA (Lou et al., 1996) . In the One is exon 9 skipping (there are 11 EAAT2 exons). Another is intron 7 retention. These defects are the ones latter case, the intron enhancer directs positive regulation of polyadenylation and contains specific binding most commonly observed and in 8 out of 30 ALS patients they are found together. What mechanism accounts for sites for PTB. Aberrant Splicing in Astrocytes, Neurodegenerative these tissue-and RNA sequence-specific defects? A gross defect in a major splicing component, such as Disease, and More RNA-Binding Proteins The current issue of Neuron reports the identification of a spliceosomal snRNP, does not provide a satisfying explanation, since this would be expected to have drasaberrant splicing events in human brain (Lin et al., 1998) that may have particular relevance to the paradigms of tic effects on the catalysis of other splicing events in the EAAT2 transcript. Another unlikely explanation is a regulated splicing mechanisms described above. This study shows a close correlation between the defects in defect in the machinery (snRNPs and auxillary proteins) that allows for splice site selection and exon definition, splicing of the glutamate transporter, EAAT2, and the sporadic form of the neurodegenerative disease, amyosince these too, are general features of splicing (informative reviews on these topics are available: Berget, 1995; trophic lateral sclerosis (ALS). Inappropriate exon-skipping events figure prominently in the types of defects Black, 1997) . Recent studies that address the molecular basis of spinal muscular atrophy make a connection observed. An additional defect is characterized by an mRNA with a retained intron and poly(A) tail, suggesting between a defect in an RNA-binding protein, survival of motor neurons protein (SMN), and pathways of snRNP that inappropriate polyadenylation may also be part of the equation. From a disease standpoint, the connection biogenesis (see, for example, Fischer et al., 1997) . But even a defect in snRNP biogenesis would appear to be between loss of the EAAT2 protein and motor neuron degeneration is satisfying. Glutamate transporters are too general to account for the specific splicing defects reported in the ALS study. The Lin et al. (1998) study required to move glutamate into cells where it can be metabolized, and astrocytes are factories that do this reports that another glutamate transporter, EAAT1 protein, is expressed normally in ALS patients, which must job. Otherwise, no extracellular mechanisms exist to perform this function. A buildup of glutamate in the exmean that EAAT1 pre-mRNA is spliced and polyadenylated normally. The EAAT1 gene has an intron/exon tracellular space is deadly for cells in the immediate vicinity, especially motor neurons.
structure similar to EAAT2. The observation that EAAT1 is normal argues for at least some pre-mRNA substrate There is a large body of literature documenting the Ehlers, M.D., Tingley, W.G., and Huganir, R.L. (1995) . Science 269, specificity. Nonetheless the study leaves us wondering 1734-1737. whether there are specific splicing defects in other Fischer, U., Liu, Q., and Dreyfuss, G. (1997) . Cell 90, 1023 Cell 90, -1029 mRNAs, or if EAAT2 is the particular target. Fu, X.-D. (1995) . RNA 1, [663] [664] [665] [666] [667] [668] [669] [670] [671] [672] [673] [674] [675] [676] [677] [678] [679] [680] It is interesting to speculate that the defect in question clusively neuronal and show region-and cell-specific Lou, H., Gagel, R.F., and Berget, S.M. (1996) . Genes Dev. 10, expression patterns in mammalian brain Darnell, 1997). In addition, the distribution and levels of Manley, J.L., and Tacke, R. (1996) . Genes Dev. 10, 1569 Dev. 10, -1579 Hu proteins change during development. The specific Min, H., Turck, C.W., Nikolic, J.M., and Black, D.L. (1997) . Genes functions of Hu proteins are not known, but their link to Dev. 11, 1023 Dev. 11, -1036 neurodegenerative disease argues that these proteins specific RNA-binding proteins that binds to specific Zhang, L., Ashiya, M., and Grabowski, P.J. (1996) . RNA 2, 682-698.
RNA structures found in introns of the glycine receptor and the Nova-1 pre-mRNA itself (Buckanovich and Darnell, 1997) . The similarity of Nova-1 to KH-type splicing regulators suggests that it might function as a splicing regulator in specific neurons of mammalian brain. Finally, a third type of RNA-binding protein, m-Msi-1, is brain-specific with an expression pattern in the adult that is astrocyte-specific (Sakakibara and Darnell, 1997). The RNA-binding proteins discussed above were discovered by the use of antisera from patients with neurodegenerative disease. How many other brain-specific proteins remain obscure for the lack of molecular probes?
Even if the ALS splicing defects are explained by a specific change in the level or activity of an RNA-binding protein, and that is a big if, the underlying molecular mechanism might be subtle and difficult to detect. Even a subtle change in the function of a splicing regulator might be all that it takes to shift the balance of control to disaster. A specific exon-skipping defect for EAAT2 could be due to a decrease in positive regulation, or to the heightened activity of a splicing repressor. In either case, the authors will need a lucky break to identify the molecular cause of this unusually novel splicing defect. Perhaps it would be worth the chance to test some of the patient antisera reactive for brain-specific RNAbinding proteins to see if aberrant protein forms or expression patterns are evident. It was not long ago that the use of antisera from patients with autoimmune disease resulted in the grand discovery of the spliceosomal snRNPs. From this discussion there is reason to hope that a better understanding of the molecular basis of neurodegenerative disease will lead both to therapeutic advances and to insights into the inner workings of splicing control.
